Factors associated with Medicaid patients' access to buprenorphine treatment

Journal of Substance Abuse Treatment

Volumn 41, Issue 1, 2011, Pages 88-96

  Baxter, Jeffrey D ^a   Clark, Robin E ^a   Samnaliev, Mihail ^a   Leung, Gary Y ^a   Hashemi, Lobat ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Buprenorphine; Medicaid; Methadone; Opioid dependence; Opioid substitution therapy

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE;

ADULT; ALCOHOLISM; ANXIETY; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG DEPENDENCE; FEMALE; HEALTH CARE ACCESS; HEART FAILURE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAID; OPIATE ADDICTION; PATIENT PREFERENCE; PRIORITY JOURNAL; SUBSTANCE ABUSE;

ADULT; BUPRENORPHINE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MEDICAID; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 79957999645     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2011.02.002     Document Type: Article

References (44)

1. Adelmann P.K. Mental and substance use disorders among Medicaid recipients: Prevalence estimates from two national surveys. Administration & Policy in Mental Health 2003, 31(2):111-129.
2. Altice F.L., Sullivan L.E., Smith-Rohrberg D., Basu S., Stancliff S., Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clinical Infectious Diseases, 43 Suppl 2006, 4:S178-S183.
3. Andersen R., Newman J.F. Societal and individual determinants of medical care utilization in the United States. Milbank Memorial Fund Quarterly - Health & Society 1973, 51(1):95-124.
4. Andersen R.M. Revisiting the behavioral model and access to medical care: Does it matter?. Journal of Health & Social Behavior 1995, 36(1):1-10.
5. Becker W.C., Fiellin D.A., Merrill J.O., Schulman B., Finkelstein R., Olsen Y., et al. Opioid use disorder in the United States: Insurance status and treatment access. Drug & Alcohol Dependence 2008, 94(1-3):207-213.
6. Broome K.M., Flynn P.M., Simpson D.D. Psychiatric comorbidity measures as predictors of retention in drug abuse treatment programs. Health Services Research 1999, 34(3):791-806.
7. Brooner R.K., King V.L., Kidorf M., Schmidt C.W., Bigelow G.E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry 1997, 54(1):71-80.
8. Center for Substance Abuse Treatment Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939 2004, Substance Abuse and Mental Health Services Administration, Rockville, MD.
9. Center for Substance Abuse Treatment Medication Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. DHHS Publication No. (SMA) 05-4048 2005, Substance Abuse and Mental Health Services Administration, Rockville, MD.
10. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug & Alcohol Dependence 2006, 81(2):103-107.
11. Conway K.P., Compton W., Stinson F.S., Grant B.F. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 2006, 67(2):247-257. [see comment].
12. DeMaria P.A., Sterling R., Weinstein S.P. The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment. American Journal on Addictions 2000, 9(2):145-153.
13. Ducharme L.J., Abraham A.J. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, & Policy 2008, 3:17.
14. Fiellin D.A. The first three years of buprenorphine in the United States: Experience to date and future directions. Journal of Addiction Medicine 2007, 1(2):62-67.
15. Jaffe J.H., O'Keeffe C. From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. Drug & Alcohol Dependence 2003, 70(2 Suppl):S3-S11.
16. Kidorf M., Disney E.R., King V.L., Neufeld K., Beilenson P.L., Brooner R.K. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug & Alcohol Dependence 2004, 74(2):115-122.
17. Kleber H.D. Methadone maintenance 4 decades later: Thousands of lives saved but still controversial. JAMA 2008, 300(19):2303.
18. Koester S., Anderson K., Hoffer L. Active heroin injectors' perceptions and use of methadone maintenance treatment: Cynical performance or self-prescribed risk reduction?. Substance Use & Misuse 1999, 34(14):2135-2153.
19. Kronick R., Gilmer T., Dreyfus T., Lee L. Improving health-based payment for Medicaid beneficiaries: CDPS (Chronic Illness and Disability Payment System). Health Care Financing Review 2000, 21(3):29.
20. Kuehn B.M. Office-based treatment for opioid addiction achieving goals. JAMA 2005, 294(7):784-786.
21. Magura S., Nwakeze P.C., Demsky S.Y. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 1998, 93(1):51-60.
22. Mark T.L., Woody G.E., Juday T., Kleber H.D. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence 2001, 61(2):195-206.
23. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction 1998, 93(4):515-532.
24. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, 1.
25. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2009, 1.
26. McCabe S.E., Cranford J.A., West B.T. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: Results from two national surveys. Addictive Behaviors 2008, 33(10):1297-1305.
27. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993, 6(9):1049-1056.
28. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction Effective medical treatment of opiate addiction. JAMA 1998, 280(22):1936-1943.
29. Okie S. A flood of opioids, a rising tide of deaths. New England Journal of Medicine 2010, 363(21):1981-1985.
30. Paulozzi L.J., Budnitz D.S., Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiology & Drug Safety 2006, 15(9):618-627.
31. Paulozzi L.J., Xi Y. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiology & Drug Safety 2008, 17(10):997-1005.
32. Rhoades H.M., Creson D., Elk R., Schmitz J., Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. American Journal of Public Health 1998, 88(1):34-39.
33. Roux P., Carrieri M.P., Villes V., Dellamonica P., Poizot-Martin I., Ravaux I., et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study. Addiction 2008, 103(11):1828-1836.
34. Rowan-Szal G.A., Chatham L.R., Simpson D.D. Importance of identifying cocaine and alcohol dependent methadone clients. American Journal on Addictions 2000, 9(1):38-50.
35. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National Findings 2009, Office of Applied Studies, Rockville, MD, (NSDUH Series H-36, HHS Publication No. SMA 09-4434).
36. Substance Abuse and Mental Health Services Administration (SAMHSA) The SAMHSA Evaluation of the Impact of the DATA Waiver Program: Summary Report (FINAL): Conducted under Task Order 277-00-6111 for SAMHSA by Westat 2006.
37. Substance Abuse and Mental Health Services Administration (SAMHSA) Results from the 2006 National Survey on Drug Use and Health: National Findings 2007, Office of Applied Studies, Rockville, MD, [NSDUH Series H-32, DHHS Publication No. SMA 07-4293].
38. Sullivan L.E., Bruce R.D., Haltiwanger D., Lucas G.M., Eldred L., Finkelstein R., et al. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clinical Infectious Diseases 2006, 43(Suppl 4):S191-S196.
39. Sullivan L.E., Chawarski M., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment?. Drug and Alcohol Dependence 2005, 79(1):113.
40. Sullivan L.E., Metzger D.S., Fudala P.J., Fiellin D.A. Decreasing international HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005, 100(2):150-158.
41. Sullivan L.E., Moore B.A., Chawarski M.C., Pantalon M.V., Barry D., O'Connor P.G., et al. Buprenorphine/Naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal of Substance Abuse Treatment 2008, 35(1):87-92.
42. Sullivan L.E., Moore B.A., O'Connor P.G., Barry D.T., Chawarski M.C., Schottenfeld R.S. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. American Journal on Addictions 2010, 19(1):53-58.
43. Turner B.J., Laine C., Lin Y.T., Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Archives of Internal Medicine 2005, 165(15):1769-1776.
44. White A.G., Birnbaum H.G., Mareva M.N., Daher M., Vallow S., Schein J., et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005, 11(6):469-479.